X

A Phase I Trial of Ublituximab, A Novel Glycoengineered Anti-CD20 mAb, In Combination With TGR-1202, A Next Generation PI3K Delta Inhibitor, In Patients With Chronic Lymphocytic Leukemia And Non-Hodgkin’s Lymphoma.

Drug Category: Array
Conference Category: Array
Lead Author: Lunning M, O'Brien S, et al.
Published Date: 21/07/2014
Download Link: https://www.tgtherapeutics.com/wp-content/uploads/2019/03/EPPLC2014-Poster2014.pdf
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top